Observational study of respiratory syncytial virus-associated hospitalizations and use of palivizumab in premature infants aged 29–32 weeks
- 21 February 2006
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 25 (2) , 120-122
- https://doi.org/10.1007/s10096-005-0082-y
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Palivizumab prophylaxis of respiratory syncytial virus disease in 2000–2001: Results from the palivizumab outcomes registryPediatric Pulmonology, 2003
- Incidence and risk factors of respiratory syncytial virus-related hospitalizations in premature infants in GermanyEuropean Journal of Pediatrics, 2003
- Respiratory syncytial virus prophylaxis—the story so farRespiratory Medicine, 2002
- EPIDEMIOLOGY OF RESPIRATORY SYNCYTIAL VIRUS INFECTION IN SOUTHERN AUSTRIAThe Pediatric Infectious Disease Journal, 2000
- Variable morbidity of respiratory syncytial virus infection in patients with underlying lung disease: a review of the PICNIC RSV databaseThe Pediatric Infectious Disease Journal, 1999
- Prevention of Respiratory Syncytial Virus Infections: Indications for the Use of Palivizumab and Update on the Use of RSV-IGIVPediatrics, 1998
- Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasiaThe Pediatric Infectious Disease Journal, 1998
- Prophylactic Administration of Respiratory Syncytial Virus Immune Globulin to High-Risk Infants and Young ChildrenNew England Journal of Medicine, 1993
- RE-HOSPITALIZATION IN THE 1ST YEAR OF LIFE FOR HIGH-RISK SURVIVORS1980